Indivior Pharmaceuticals (INDV) Liabilities and Shareholders Equity (2023 - 2026)

Indivior Pharmaceuticals' Liabilities and Shareholders Equity history runs 4 years deep, the most recent figure standing at $1.2 billion for Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity fell 12.95% year-over-year to $1.2 billion in Q1 2026; TTM through Mar 2026 was $5.3 billion, a 95.69% increase from a year earlier, with the FY2025 full-year figure at $1.2 billion, down 8.74% from the prior year.
• Liabilities and Shareholders Equity was little changed at $1.2 billion in Q1 2026 per INDV's latest filing, from $1.2 billion in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $1.8 billion in Q4 2023 and bottomed at $1.2 billion in Q1 2026.
• The 4-year median for Liabilities and Shareholders Equity is $1.4 billion (2025), against an average of $1.4 billion.
• Across the five-year window, Liabilities and Shareholders Equity retreated 25.14% in 2024 and decreased 8.74% in 2025, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $1.8 billion in 2023, then retreated by 25.14% to $1.3 billion in 2024, then retreated by 8.74% to $1.2 billion in 2025, then retreated by 0.33% to $1.2 billion in 2026.
• Per Business Quant, the three latest INDV Liabilities and Shareholders Equity figures stand at $1.2 billion (Q1 2026), $1.2 billion (Q4 2025), and $1.4 billion (Q3 2025).